Article
Cilostazol, a potent phosphodiesterase type III inhibitor, selectively increases antiatherogenic high-density lipoprotein subclass LpA-I and improves postprandial lipemia in patients with type 2 diabetes mellitus.
Metabolism: clinical and experimental - 1 Oct 2002
Ikewaki Katsunori, Mochizuki Keiko, Iwasaki Masafumi, Nishide Ryoichi, Mochizuki Seibu, Tada Norio
Abstract excerpt
Low levels of high-density lipoproteins cholesterol (HDL-C) as well as impaired postprandial lipemia are known to be associated with the increased risk for coronary artery disease (CAD) in patients with type 2 diabetes mellitus (type 2 DM). HDL are heterogeneous in size and apolipoprotein composition. Recent evidence indicates that among the 2 major HDL subclasses, those without apolipoprotein A-II (LpA-I) are...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.